Elahere is a targeted treatment option for Canadians living with FRα-positive, platinum-resistant ovarian cancer.

The European Medicines Agency (EMA) has determined that the medicinal product Elahere (mirvetuximab soravtansine, AbbVie Deutschland), indicated for the treatment of adults with folate receptor alpha ...

Add Yahoo as a preferred source to see more of our stories on Google. AbbVie is running a Phase III trial of Elahere in PSOC AbbVie's Elahere has shown a 62.7% objective response rate (ORR) in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AbbVie is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully been completed for ELAHERE® (mirvetuximab soravtansine for injection), and that a ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha ...

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Par ...

Genmab may have arrived in Spain with updated data from a pair of phase 2 studies from the main prize of its Merus buyout, ...

AbbVie’s Elahere has shown a 62.7% objective response rate (ORR) in patients with platinum-sensitive ovarian cancer (PSOC) in a Phase II trial. In the IMGN853-0420 study (NCT05456685), Elahere ...

AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking approval for its ovarian cancer drug Elahere ...